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Smokers are more susceptible to respiratory viral infections, in-
cluding influenza virus, but the mechanisms mediating this effect
are unknown. To determine how epithelial cells contribute to the
enhanced susceptibility seen in smokers, we established an in vitro
model of differentiated nasal epithelial cells (NECs) from smokers,
which showed enhanced mucin expression. The NECs from smokers
responded to influenza infection with greater cytotoxicity, release of
interleukin-6, and viral shedding than NECs from nonsmokers.
Focusing on type I interferon (IFN) expression, we observed that
influenza-infected NECs from smokers produced significantly less
IFN-a than NECs from nonsmokers. Similarly, the expression of IRF7,
a key transcription factor controlling the expression of IFN-a, was
significantly decreased in influenza-infected and IFN-b–stimulated
NECs from smokers. Furthermore, our data indicate that the DNA
methylation of the IRF7 gene and expression of the DNA (cytosine-5-)-
methyltransferase1 wasenhanced in NECs fromsmokers.To confirm
these findings in vivo, we initiated a study in which smoking and
nonsmoking healthy volunteers were inoculated nasally with the
live-attenuated influenza virus (LAIV) vaccine, and nasal biopsies
wereobtainedbefore and after the administrationof LAIV. The LAIV-
induced expression of IRF7 was lower in the nasal epithelium from
smokers, supporting our in vitro observations. These data demon-
strate that infection with influenza results in the reduced expression
of transcription factor IRF7 in NECs from smokers, and that these
effects may be mediated by an epigenetic modification of the IRF7
gene, thus providing a potential mechanism rendering smokers
more susceptible to respiratory virus infections.
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Viral infections of the respiratory tract are a major cause of
morbidity and mortality, especially in children and the elderly
(1, 2). In the United States alone, more than 20,000 people die
and more than 100,000 are hospitalized every year because of
influenza virus-related diseases. Despite large-scale vaccination
efforts and antiviral therapies, the morbidity and mortality
associated with influenza have not significantly changed recently
(3, 4). Epidemiologic studies show that smokers are more sus-
ceptible to influenza virus infections than nonsmokers (5–7), but
the mechanisms mediating these effects are not known. Labora-
tory animal studies and human epidemiologic evidence indicate
that adaptive immune responses, as marked by influenza-specific
antibody production, are unaffected by chronic cigarette smoke
exposure (6, 8, 9). Thus, the effects of cigarette smoke on sus-
ceptibility to influenza infection may involve antiviral defense
responses of cells local to the airway, such as the host epithelium.
Recent evidence suggests that antiviral defense responses, such
as virus-induced apoptosis and type I interferon (IFN) signaling,
are suppressed in cells exposed acutely to cigarette smoke (10,
11). However, whether and how chronic exposure to cigarette
smoke affects antiviral defense responses remain unknown.
Airway epithelial cells are the primary site for influenza virus
infection and replication. Virus-infected epithelial cells respond
to influenza infection by synthesizing and releasing numerous
cytokines, immunoregulatory molecules, and antiviral media-
tors. Among the mediators released by epithelial cells upon
infection with influenza, regulated upon activation, normal T
cell expressed and secreted, monocyte chemotactic protein-1,
IL-8, IL-6, and eotaxin recruit and activate proinflammatory
cells, whereas type I interferons (IFN-a and IFN-b) induce the
synthesis and/or activity of mediators involved in turning off
viral replication within the host cell. The expression of type I
IFNs is controlled by interferon regulatory factors (IRFs) 3 and
7 (12). Specifically, viral infection triggers signaling cascades
that culminate in the phosphorylation and activation of preex-
isting cytosolic IRF3 and IRF7, which stimulate predominantly
the production of small amounts of IFN-b. Released IFN-b
stimulates the type I IFN receptor (IFNAR) in an autocrine/
paracrine fashion, leading to the activation of IFN-stimulated
gene factor 3 and the de novo transcription of the IRF7 gene.
Newly synthesized IRF7 further amplifies the type I IFN re-
sponse by inducing the transcription of IFN-b and IFN-a, thus
activating a larger ‘‘second wave’’ of type 1 IFN production and
a positive feedback loop.
The differentiation of primary human epithelial cells under
defined culture conditions in vitro results in a pseudostratified
epithelium that emulates many characteristics found in human
airway epithelium in vivo (13). We developed an in vitro model
of nasal epithelial cells (NECs) obtained from current smokers,
which when differentiated in vitro maintain the characteristics
found in nasal epithelia in smokers in vivo and therefore
provide an important tool for examining potential cellular
mechanisms that mediate an enhanced susceptibility to influ-
enza virus infections in smokers. Using this model as well as
nasal epithelial biopsies obtained from subjects infected with
the live-attenuated influenza virus (LAIV) vaccine, we performed
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experiments to test the hypothesis that chronic exposure to cig-
arette smoke modifies the ability of NECs to mount antiviral
defense responses.
MATERIALS AND METHODS
Nasal Epithelial Cell Culture and Infection with Influenza
Primary human NECs were obtained from healthy smoking and non-
smoking adult volunteers by gently stroking the inferior surface of the
turbinate several times with a Rhino-Probe curette (Arlington Scien-
tific, Arlington, TX), which was inserted through a nasoscope. The
selection criteria for subject recruitment were similar to those de-
scribed previously (14). Briefly, subjects were aged 18 to 40 years, and
identified themselves as generally healthy and without a diagnosis for
any smoking-related disorder or history of asthma. Smoking status was
assessed via questionnaire, and confirmed through urine cotinine
analysis (14). All smokers recruited for the study were current smokers.
This protocol was approved by the Institutional Review Board for
Biomedical Research of the University of North Carolina School of
Medicine.
Primary human NECs were expanded to passage 2 in bronchial
epithelial growth medium (Cambrex Bioscience Walkersville, Inc.,
Walkersville, MD), plated on collagen-coated filter supports with a
0.4-mM pore size (Trans-CLR; Costar, Cambridge, MA), and cul-
tured in a 1:1 mixture of bronchial epithelial cell basic medium and
Dulbecco’s minimal essential medium with SingleQuot supplements
(Cambrex), bovine pituitary extracts (13 mg/ml), bovine serum albu-
min (1.5 mg/ml), and nystatin (20 units). Upon confluence, all-trans
retinoic acid was added to the medium, and air–liquid interface (ALI)
culture conditions (i.e., removal of the apical medium) were created to
promote differentiation. Mucociliary differentiation was achieved 18 to
21 days after ALI.
For in vitro experiments, we used influenza A/Bangkok/1/79 (H3N2
serotype), which was propagated in 10-day-old embryonated hen’s
eggs. The virus was collected in the allantoic fluid and titered by a 50%
tissue-culture infectious dose (TCID50) in Madin-Darby canine kidney
cells and hemagglutination as described before (15). Stock virus was
aliquoted and stored at 2808C until use. Unless otherwise indicated,
for infection, approximately 5 3 105 cells were infected with approx-
imately 128 hemagglutination units of influenza A/Bangkok/1/79, which
resulted in approximately 10% of cells being infected with influenza 24 h
after infection. Total RNA, basolateral supernatants, and apical washes
were collected 24 h after infection.
RT-PCR
Total RNA was extracted using TRizol (Invitrogen, Carlsbad, CA)
according to the supplier’s instructions. First-strand cDNA synthesis
and real-time RT-PCR were performed as described previously (15,
16). The mRNA analyses were performed using commercially available
primer and probe sets (inventoried Taqman Gene Expression Assays)
purchased from Applied Biosystems (Foster City, CA).
Cytokine and Lactate Dehydrogenase Analysis
Basolateral media were collected 24 hours after infection and analyzed
for IFN-a or IL-6, using commercially available ELISA kits according
to the supplier’s instructions (Pierce, Rockford, IL). Cell viability was
assessed by analyzing cell culture supernatants for lactate dehydroge-
nase (LDH) activity, using a commercially available kit according to
the supplier’s instructions (CytoTox 96; Promega, Madison, WI).
Influenza Virus Titer
Influenza virus titers in apical washes were determined by a TCID50 in
Madin Darby canine kidney (MDCK) cells, and evaluated using the
agglutination of red blood cells as an indicator, according to a modified
protocol described previously (17). Briefly, MDCK cells grown in
round-bottom 96-well plates were inoculated with virus-containing
samples diluted in serum-free Eagle’s minimum essential medium
containing 20 mg/ml trypsin, using log10 dilutions. After 3 days of
incubation, a suspension of human erythrocytes (0.5%) was added to
each well. Wells exhibiting hemagglutination were considered positive,
and virus titers were expressed as the TCID50.
Western Blotting
Whole cell lysates were prepared by lysing the cells in radioimmunopre-
cipitation assay buffer containing 1% Nonidet P-40, 0.5% deoxycholate,
0.1% SDS, and protease inhibitors (Cocktail Set III; Calbiochem, San
Diego, CA), as well as phosphatase inhibitors (0.5 mM NaVO4 and 1 mM
b-glycerophosphate). Whole cell lysate (100 mg) was separated by SDS-
PAGE followed by immunoblotting, using specific antibodies to IRF7,
IRF3 (Santa Cruz Biotechnology, Santa Cruz, CA), or b-actin (1:2,000;
US Biological, Swampscott, MA), which was used as a loading control.
Antigen-antibody complexes were stained with anti-rabbit or anti-mouse,
horseradish peroxidase (HRP)-conjugated antibody (1:4,000; Santa Cruz
Biotechnology) and SuperSignal West Pico Chemiluminescent Substrate
(Pierce). Chemiluminescent signals were acquired using a 16-bit CCD
camera (GeneGnome System; Syngene, Frederick, MD), and visualized
using GeneSnap software (Syngene). Densitometric quantification was
performed using GeneTools analysis software (Syngene).
Analysis of DNA Methylation
Genomic DNA isolated from NECs of smokers and nonsmokers was
analyzed for DNA methylation in the promoter site region of the
human IRF7gene, using Methyl-Profiler DNA Methylation qPCR
Assays according to the supplier’s instruction (SABiosciences Corp.,
Frederick, MD). Briefly, Genomic DNA was isolated using a QIAamp
DNA Mini Kit (Qiagen, Valencia, CA), including the recommended
removal of potential RNA contamination using RNase. The Methyl-
Profiler DNA Methylation qPCR Assay is based on the digestion of
unmethylated and methylated DNA, using methylation-sensitive and
methylation-dependent restriction enzymes. The remaining DNA after
digestion is quantified by real-time RT-PCR, using primers that
specifically flank the region of interest, immediately upstream from
the transcriptional start site of the IRF7 gene (18). For this analysis, the
relative concentrations of differentially methylated DNA (specifically
hypermethylated, unmethylated, and intermediary methylated DNA)
are determined by comparing the amount of each digest with that of
a mock digest. For each sample, data are expressed as the sum of the
percent hypermediary and intermediary methylated DNA.
Immunohistochemistry
Cells were fixed with ice-cold acetone for 20 minutes, washed with Tris-
buffered saline (TBS), and blocked with Powerblock (Biogenex, San
Ramon, CA) for 1 hour at room temperature. Afterward, cells were
incubated with primary antibody overnight at 48C. The antibodies in-
cluded anti-Muc5B (Millipore, Billerica, MA), anti-acetylated a-tubulin
used at 1:800 (Invitrogen), which recognizes cilia, or anti-IRF7 (Santa
Cruz Biotechnology). After incubation with the primary antibodies,
samples were washed with TBS, followed by incubation with secondary
antibodies at 1:200 for 1 hour at room temperature. For confocal
microscopy, Alexa 568–conjugated goat anti-mouse and Alexa 488–
conjugated goat anti-rabbit antibodies (both from Invitrogen) were
used. After incubation with the secondary antibodies, samples were
washed with TBS and visualized by confocal microscopy, using a
Nikon C1Si, and the images were processed using EZ-C1 FreeViewer
software (Nikon, Melville, NY). For the visualization of IRF7 levels,
5-mm sections were placed on Superfrost/plus slides (Fisher Scientific,
Pittsburgh, PA) and stained for IRF7, using anti-IRF7 antibodies
(Santa Cruz Biotechnology). After incubation with HRP-conjugated
secondary antibodies, samples were washed with TBS and evaluated
under light microscopy. As a control, sections were also incubated
without the primary antibody, to detect nonspecific binding of the
HRP-conjugated secondary antibody.
Inoculation of Subjects with LAIV
Healthy smoking and nonsmoking volunteers between ages 18 and 35
years were recruited for this study, and assessed for their smoking status
by questionnaire and urine cotinine analysis. Specific exclusion criteria
included a history of asthma, chronic obstructive pulmonary disease
(COPD), cardiac disease, or any chronic cardiorespiratory condition; any
type of immunodeficiency; a previous known illness diagnosed specifi-
cally as influenza; current pregnancy; or egg allergy. The screening pro-
tocol included specific testing to rule out HIV infection and pregnancy.
After an initial screening visit (z3–6 wk previously), volunteers were
inoculated nasally with the LAIV vaccine (FluMist; MedImmune, Inc.,
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Gaithersburg, MD), according to the manufacturer’s recommendations.
Throughout the study, FluMist 2006–2007 and 2007–2008 were used,
which are based on the strains A/New Caledonia/20/99 (H1N1) for
2006–2007 and A/Solomon Islands/3/2006 (H1N1) for 2007–2008, as
well as A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 for
both years. Nasal biopsies from both nostrils were obtained 3–6 wk
before (screening visit) and 4 days after inoculation with LAIV, as
described previously. Tissue from one nostril was immediately fixed in
4% paraformaldehyde for subsequent analysis using immunohisto-
chemistry, whereas the sample from the other nostril was immediately
processed for isolation of RNA. Although some overlap existed, the
LAIV inoculation study was separate from the study obtaining NECs
for in vitro culture described previously, and in consequence, the
subject pools were generally different. This protocol was approved by
the Institutional Review Board for Biomedical Research of the
University of North Carolina School of Medicine.
Statistical Analysis
All data are expressed as mean 6 SEM. Data were analyzed using either
the Student t test or a one-way ANOVA and Newman-Keuls post hoc
analysis. A value of P , 0.05 was considered significant.
RESULTS
In Vitro Model of NECs from Smokers
Biopsies obtained from smokers and nonsmokers were analyzed
for the expression of mucin. One of the major mucins produced
by differentiated airway epithelial cells (19, 20), Muc5B, was
enhanced in nasal biopsies from smokers, as shown by immu-
nohistochemistry (Figure 1A) and Muc5B mRNA concentra-
tions (Figure 1B). Differentiated NECs from smokers and
nonsmokers were analyzed for the production of mucosubstan-
ces and the expression of specific mucins. Differences in the
expression of Muc5B were maintained after culturing NECs
in vitro, as shown by the increased number of cells staining
positively for Muc5B (Figure 1C) and the increased Muc5B
mRNA concentrations seen in NECs from smokers compared
with nonsmokers (Figure 1D). These data confirm the notion
that Muc5B expression is enhanced in smokers (21), and that
this change is maintained in differentiated NECs in long-term
in vitro cell culture.
Effects of Influenza Virus on NECs from Smokers
and Nonsmokers
We next determined whether NECs from smokers exhibited
modified influenza-induced cell responses. Using a similar in-
fection protocol as described elsewhere (15, 16), we measured
concentrations of LDH released into the basolateral superna-
tants as a marker of influenza-induced cytotoxicity, concentra-
tions of IL-6 as a marker of influenza-induced inflammatory
mediator release, and viral replication in NECs. Influenza-
induced cytotoxicity was significantly enhanced in NECs from
smokers, but not nonsmokers, compared with their noninfected
control subjects (Figure 2A). Similarly, the influenza-induced
release of IL-6 into basolateral supernatants was significantly
greater in NECs from smokers than in nonsmokers (Figure 2B).
Moreover, Figure 2C shows that influenza virus replication was
significantly greater in NECs from smokers.
To determine potential mechanisms mediating the enhanced
effects of influenza virus infections seen in NECs from smokers,
we assessed whether the influenza-induced expression of anti-
viral defense mediators was modified. Specifically, we analyzed
the influenza-induced expression of IFN-a in NECs from
smokers and nonsmokers. Whereas infection with influenza
significantly increased the release of IFN-a over noninfected
cells in NECs from nonsmokers, the influenza-induced release
of IFN-a was significantly reduced in differentiated NECs from
smokers compared with nonsmokers (Figure 3A). Furthermore,
the expression of IFN-b was significantly enhanced in NECs
from both smokers and nonsmokers, with similar influenza-
induced IFN-b mRNA concentrations in both groups (Figure
3B). Because the influenza-induced IFN-b expression did not
appear to be different in NECs from smokers and nonsmokers,
and because of its key role in regulating the expression of IFN-
a, we measured influenza-induced IRF7 expression in NECs
Figure 1. Increased Muc5B expression in nasal epithelial cells from
smokers. (A) Nasal biopsies were immunohistochemically labeled using
anti-acetylated a-tubulin (cilia, red), Muc5B (green), and nuclei (49,6-
diamidino-2-phenylindole; blue), and visualized using confocal micros-
copy (arrows indicate Muc5B-positive cells). (B) Total RNA isolated from
nasal biopsies was analyzed for levels of Muc5B mRNA, and normalized
for expression of b-actin (n 5 20 smokers; n 5 13 nonsmokers). (C ) In
vitro differentiated NECs were immunohistochemically labeled using
anti-Muc5B and HRP-conjugated secondary antibodies. Sections were
visualized en face by light microscopy (arrows indicate Muc5B-positive
cells). (D) Total RNA isolated from differentiated NECs from smokers
and nonsmokers was analyzed for concentrations of Muc5B mRNA and
normalized for the expression of b-actin (n 5 12 smokers; n 5 16
nonsmokers). *Significantly different from nonsmoker NECs (P , 0.05).
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from smokers and nonsmokers. Influenza-induced IRF7 mRNA
(Figure 4A) concentrations were greater in NECs from
nonsmokers than smokers. Similarly, protein levels of IRF7
increased in response to influenza infection in NECs from
nonsmokers, whereas no such increase was observed in smokers
(Figure 4B). The expression of IRF3 was the same in both
infected and noninfected NECs from smokers and nonsmokers.
A densitometric analysis demonstrated that influenza-induced
IRF7 expression was significantly greater in NECs from non-
smokers than smokers (Figure 4C). These data indicate that the
ability to enhance IRF7 expression in response to influenza
virus is significantly reduced in NECs from smokers.
To test further whether the reduced release of IFN-a seen in
Figure 3A was mediated by impaired type I IFN signaling and
the ability to enhance IRF7 expression, we stimulated NECs
from smokers and nonsmokers with IFN-b, which induces the
production of IFN-a via an IRF7-dependent positive feedback
loop (22). Our previous studies demonstrated that the receptor
for IFN-b is predominantly localized on the basolateral side of
the epithelium, which is why we only added IFN-b to the
basolateral compartment to stimulate IFN-dependent gene
expression (23). Figure 5 shows that the IFN-b–induced expres-
sion of IRF7 was significantly lower in NECs from smokers than
in those from nonsmokers, at both the mRNA (Figure 5A) and
protein (Figure 5B) levels.
Potential Role of Epigenetic Mechanisms Mediating
Suppressed IRF7 Expression
Figure 1 and previous reports indicate that airway epithelial
cells obtained from defined diseased populations can maintain
specific functional characteristics after differentiation in vitro
(24, 25). To determine the potential mechanisms mediating the
long-term maintenance of phenotypic and functional character-
istics ex vivo, which are also reflected by a decreased ability to
produce antiviral mediators, we assessed epigenetic modifica-
tions of the IRF7 gene. Previous studies demonstrated that
methylation of the IRF7 gene results in gene silencing and
a decreased ability of type I IFN to induce gene expression (26).
Using a quantitative PCR-based DNA methylation analysis, we
found that the IRF7 gene was significantly more methylated in
NECs from smokers compared with nonsmokers (Figure 6A).
Figure 2. The NECs from smokers are more susceptible to influenza
virus than are the cells from nonsmokers. The NECs from smokers and
nonsmokers were infected with influenza A/Bangkok/2/79. Basolateral
supernatants collected 24 hours after infection were assessed for (A)
LDH and (B) IL-6 (n 5 13 smokers; n 5 15 nonsmokers). (C ) Apical
supernatants collected 24 hours after infection were analyzed for viral
replication (n 5 21 smokers; n 5 13 nonsmokers). *Significantly
different from noninfected cells (P , 0.05). #Significantly different
from nonsmokers (P , 0.05).
Figure 3. Influenza-induced IFN-a and IFN-b expression by NECs from
smokers and nonsmokers. The NECs were infected with influenza A
Bangkok/2/79 or left uninfected, and analyzed 24 hours after infection.
(A) Basolateral supernatants were analyzed for IFN-a concentrations
(n 5 7 smokers; n 5 12 nonsmokers). (B) Total RNA was analyzed for
IFN-b mRNA concentrations (n 5 6 smokers; n 5 9 nonsmokers).
*Significantly different from noninfected cells (P , 0.05). #Significantly
different from smokers (P , 0.05).
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In addition, we examined the expression of DNA (cytosine-5-)-
methyltransferase 1 (DNMT1), a DNA methyltransferase that
copies DNA methylation patterns within the DNA to the
daughter strands during DNA replication. Figure 6B shows that
DNMT1 mRNA levels were higher in cultured NECs from
smokers compared with nonsmokers. These data are consistent
with the hypothesis that chronic smoke exposure reduces type I
IFN responses to influenza virus, and that this may be associ-
ated with epigenetic modifications of the IRF7 gene.
In Vivo Confirmation of Suppressed Influenza-Induced IRF7
Expression in NECs from Smokers
To test whether similar effects occur in smokers in vivo, we
obtained nasal epithelial biopsies at baseline and 4 d after the
inoculation of volunteers with LAIV. The expression of IRF7
was examined in nasal biopsies, using real-time RT-PCR and
immunohistochemistry. The LAIV-induced IRF7 mRNA con-
centrations were greater in nasal biopsies from nonsmokers
compared with smokers, although not at a statistically signifi-
cant level (P 5 0.05) (Figure 7A). Immunohistochemical
staining demonstrated that IRF7 was minimally expressed at
baseline, and was robustly expressed in nonsmokers 4 d after
infection with LAIV (Figure 7B, upper panels), but not in
smokers (Figure 7B, lower panel). These results appeared
consistent with our observations made in vitro regarding the
suppression of influenza-induced IRF7 expression in smokers.
DISCUSSION
Epidemiologic evidence and experimental data suggest that
exposure to cigarette smoke increases the susceptibility to and
severity of respiratory virus infections (5, 6, 8, 9). We developed
an in vitro model of NECs from smokers that maintains the
phenotypic changes observed in the nasal epithelium in this
group in vivo. Using this experimental model, our data indicate
that NEC from smokers may be more susceptible to influenza
virus infections, and that this susceptibility is associated with a
suppressed ability to upregulate IFN-a expression after infec-
tion. In addition, we found that the ability of virus to induce
expression of the key IFN pathway transcription factor IRF7
was also suppressed in cells from smokers, and that this sup-
pression was associated with increased DNA methylation of the
IRF7 gene. Using responses induced by the temperature-
sensitive LAIV vaccine as a model for transient, self-limited
infection, we also found that the influenza-induced expression
of IRF7 was suppressed in the nasal epithelium in smokers
in vivo. Thus, our data suggest that chronic exposure to cigarette
smoke modifies the antiviral defense responses of the respiratory
epithelium, and that epigenetic modifications of a key antiviral
defense gene could mediate these effects.
Our study focused on early events in the course of viral
infection, that is, the results of the initial interaction between
virus and host epithelial cells. The respiratory epithelium is the
Figure 4. Expression of IRF7 in NECs from smokers and nonsmokers.
The NECs were infected with influenza A Bangkok/2/79 or left un-
infected, and analyzed for IRF7 expression 24 hours after infection. (A)
Total RNA was analyzed for IRF7 mRNA and normalized to b-actin
mRNA concentrations (n 5 16 smokers; n 5 14 nonsmokers). (B)
Whole cell lysates were analyzed for IRF7 and IRF3 protein levels by
Western blotting. Membranes were stripped and analyzed for b-actin
to assure equal loading. Representative immunoblots are shown. (C )
Densitometric analysis of IRF7 protein levels (n 5 6 smokers; n 5 6
nonsmokers). *Significantly different from noninfected cells (P , 0.05).
#Significantly different from smokers (P , 0.05).
Figure 5. Interferon-induced IRF7 expression in NECs from smokers
and nonsmokers. The NECs were stimulated with 1 ng/ml IFN-b from
the basolateral side, and analyzed for IRF7 expression 24 hours after
infection (n 5 7 smokers; n 5 7 nonsmokers). (A) Total RNA was
analyzed for IRF7 mRNA, normalized to b-actin mRNA levels, and
expressed as fold induction over the respective control. (B) Whole cell
lysates were analyzed for IRF7 protein levels by Western blotting.
Membranes were stripped and analyzed for b-actin to assure equal
loading. Representative immunoblots are shown. *Significantly differ-
ent from nonsmokers (P , 0.05).
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main target of respiratory viruses, is the main site for viral
replication, and plays an important role during initial antiviral
defense responses. Viral infection normally induces the pro-
duction of type I IFNs, which in turn activate the synthesis
of interferon-stimulated genes, and in consequence, limit viral
replication (29). Previous studies demonstrated that virus-
induced interferon production is suppressed in epithelial cells
from diseased populations. Specifically, bronchial epithelial
cells from patients with asthma exhibited blunted IFN-b and
IFN-l expression after infection with rhinovirus (27, 28). Thus,
in bronchial epithelial cells from patients with asthma, virus-
induced interferon production is significantly reduced. How-
ever, the present data indicate that influenza infection resulted
in a similar upregulation of IFN-b expression, although the
ability of influenza to enhance IFN-a expression was signifi-
cantly reduced in NECs from smokers. As indicated previously,
a positive feedback loop that amplifies type I IFN production
after the initial virus-dependent production of IFN-b is de-
pendent on IRF7 (12). In addition to infection with influenza,
stimulation with IFN-b also resulted in the suppressed expres-
sion of IRF7 in NECs from smokers. Thus, in NECs from
smokers, the action, rather than the production, of IFN-b
appears to be blunted. Other factors being equal, we would
expect this to result in a poorer ability to clear virus from the
nasal passages. Consequently, the suppression of elements of
type I IFN signaling could play a role in the increased
susceptibility to infection observed in epidemiologic studies of
smokers and those exposed to second-hand smoke.
An interesting finding in our study involved the retention of
histologic and functional differences between NECs from
smokers and nonsmokers, despite the long-term culture of cells
in vitro. Several groups demonstrated that epithelial cells
obtained from defined disease populations, when differentiated
in vitro, maintain many of their phenotypic and functional
characteristics found in vivo (24, 25). For example, bronchial
epithelial cells obtained from patients with asthma maintain
increased basal cytokine production in vitro (24). Cultured
bronchial epithelial cells from patients with COPD demonstrate
a greater ability to induce Muc5AC expression than cells
obtained from normal subjects, which corresponds to similar
observations made in vivo (30). In our model, the expression of
Muc5B, the major mucin found in the sputum of patients with
COPD (21), was enhanced both in nasal biopsies from smokers
in vivo and in differentiated NECs from smokers in vitro. In
addition, recent data from our group also indicate that ciliary
phenotypes, such as percent ciliated cells and ciliary beat
frequency, are different in the nasal epithelium of smokers,
which is a phenotype also maintained in differentiated NECs
in vitro (17) (J. L. Carson, personal communication). Thus, dif-
ferentiated NECs obtained from smokers maintain characteristics
found in the nasal epithelium in these individuals in vivo, and
therefore provide a viable model for studying cellular mechanisms
by which exposure to cigarette smoke modifies antiviral defense
responses at the level of the epithelium.
One mechanism for producing lasting changes in cellular
function and gene expression is gene silencing through the
DNA methylation of discrete CpG islands. Patterns of DNA
methylation are faithfully propagated through cell division by
copying existing methylation patterns during DNA replication,
using the parental strand as a template. Previous studies dem-
onstrated that hypermethylation of the IRF7 gene results in
a decreased ability of type I IFNs to induce gene expression (18,
26). The present data indicate that the IRF7 gene is methylated,
and that the expression of DNMT1 is increased in NECs from
smokers. The region of the IRF7 gene that was analyzed here is
in close proximity to the transcriptional start site, is within the
Figure 6. IRF7 gene DNA
methylation and expression
of DNMT1 in NECs. (A) Ge-
nomic DNA isolated from
NECs from smokers and
nonsmokers was analyzed
for DNA methylation of the
IRF7 gene, using a quantita-
tive PCR-based DNA meth-
ylation assay. The data are
presented as percent meth-
ylated DNA (n 5 6 smokers;
n 5 6 nonsmokers). (B) To-
tal RNA isolated from NECs
of smokers and nonsmokers
was analyzed for DNMT1
mRNA concentrations, and
normalized for the expres-
sion of b-actin mRNA levels




Figure 7. Influenza-induced IRF7 expression in vivo. Nasal biopsies
were obtained from smokers and nonsmokers 2–4 weeks before
(baseline) and 4 days after administration of LAIV, and were examined
for the expression of IRF7. (A) Total RNA was analyzed for IRF7 mRNA,
normalized to b-actin mRNA levels, and expressed as fold induction
over the subject-specific baseline level (n 5 12 smokers; n 5 13
nonsmokers). (B) Nasal biopsies were fixed, and paraffin-embedded
sections were immunohistochemically stained using antibodies against
IRF7 and visualized by light microscopy. C, cilia.
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promoter region of the IRF7 gene, and was previously shown
to be important for silencing the IRF7 gene in response to
stimulation with IFN-a (18). In addition to IRF7, a number of
other host defense genes, such as IFNg, STAT1, COX2, and
ICSBP/IRF8, which also play important roles in host defense
responses against viruses, were shown to be silenced by DNA
methylation under various circumstances, including exposure to
cigarette smoke (31). Therefore, cigarette smoke-induced epige-
netic modification is likely to exert an impact on additional genes
beyond IRF7 that are important in the host response to viral
infection.
Our data demonstrate that the expression of DNMT1 is
enhanced in NECs from smokers. Whereas DNMT3a and
DNMT3b are capable of a de novo methylation of symmetri-
cally unmethylated CpGs, DNMT1 faithfully propagates DNA
methylation patterns through cell divisions, and the enhanced
expression of DNMT1 is associated with hypermethylation, in
bronchial epithelial cells (32). A number of compounds in ciga-
rette smoke are capable of promoting DNA methylation (33, 34),
and it has become increasingly apparent that this is one of the
major mechanisms of gene silencing of tumor-suppressor genes
(35, 36). Nicotine-derived nitrosamine ketone, a component of
cigarette smoke, increased the expression and activity of DNMT1
in respiratory epithelial cells of mouse lungs (37), and DNMT1 is
highly expressed in lung tumors from smokers, in association with
increased DNA methylation and the gene silencing of tumor-
suppressor genes such as p16(INK4a) (38). In addition, the
decreased expression of DNMT1 resulted in a reversal of both
hypermethylation and gene silencing in bronchial epithelial cells
(32), further supporting the significance of this enzyme in the
context of epigenetic changes.
Interestingly, our observations appear to be in contrast to
those in a previous study demonstrating that mice exposed to
cigarette smoke for 2 weeks and subsequently stimulated with
polyinosinic:polycytidylic acid had increased levels of type I
IFNs in bronchoalveolar lavage fluid (39). Similarly, airway
epithelial cells exposed to cigarette smoke condensate and
infected with respiratory syncytial virus showed a greater
expression of IRF7 (40). However, mice exposed to cigarette
smoke for 3 to 5 months and infected with a low dose of influenza
virus showed decreased inflammatory responses, whereas mice
infected with high doses of influenza after smoke exposure showed
increased inflammatory responses (8). Thus, the effects of cigarette
smoke on viral infection and subsequent inflammatory or antiviral
responses may depend on the specific viral pathogen, level of
infection, and chronicity of smoke exposure.
The overall response of the respiratory tract to viral infection
involves not only direct virus–epithelium interactions, but also
a large array of innate and adaptive immune responses that
determine the outcome of infection. Thus, studies of systemic
immune responses to virus in smokers are relevant to our study.
In this regard, influenza-specific antibody levels were reported
not to be different in smokers compared with nonsmokers (6).
In addition, influenza-specific memory responses upon rechal-
lenge were not altered by chronic exposure to cigarette smoke
in mice (8). Further research is required to define the impact of
cigarette smoke-associated suppression of epithelial antiviral
responses on the complex overall response to influenza in the
human respiratory tract.
In conclusion, our data strongly suggest that chronic expo-
sure to cigarette smoke suppresses epithelial antiviral (type 1
IFN) pathways in human nasal epithelium. This likely results in
an increased susceptibility to viral infection, and these effects
may be mediated by the gene silencing of key antiviral defense
pathway mediators, including IRF7. Viral infections remain
a major public health concern and a likely cause of exacerba-
tions of smoking-related diseases, such as COPD (41). Un-
derstanding the mechanisms by which exposure to cigarette
smoke enhances susceptibility to viral infections could lead to
new strategies for minimizing influenza-induced morbidity and
even mortality. For example, potential therapeutic strategies
could include interventions or reversals of epigenetic modifica-
tions induced by cigarette smoke, which were already shown to
improve glucocorticoid sensitivity in patients with COPD (42),
and to reverse the markers of cigarette smoke–induced cancer
using in vitro and animal in vivo models (43).
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